Pyrukynd

Active Ingredient(s): Mitapivat Sulfate
FDA Approved: * February 17, 2022
Pharm Company: * AGIOS PHARMS INC
Category: Anemia

Mitapivat, sold under the brand name Pyrukynd, is a medication used to treat hemolytic anemia.[1] It is taken as the sulfate hydrate salt by mouth.[1] Mitapivat is a pyruvate kinase activator.[1] Mitapivat was approved for medical use in the United States in February 2022.[1][2][3] Contents 1 Medical uses 2 Pharmacology 2.1 Mechanism of action 3 Society and culture 3.1 Names 4 References 5 ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Pyrukynd 5 mg Oral Tablet, Film Coated
NDC: 71334-205
Labeler:
Agios Pharmaceuticals, Inc.
Pyrukynd 20 mg Oral Tablet, Film Coated
NDC: 71334-210
Labeler:
Agios Pharmaceuticals, Inc.
Pyrukynd 50 mg Oral Tablet, Film Coated
NDC: 71334-215
Labeler:
Agios Pharmaceuticals, Inc.
Pyrukynd 5 mg Oral Tablet, Film Coated
NDC: 71334-220
Labeler:
Agios Pharmaceuticals, Inc.
PyrukyndPyrukynd Kit
NDC: 71334-225
Labeler:
Agios Pharmaceuticals, Inc.
PyrukyndPyrukynd Kit
NDC: 71334-230
Labeler:
Agios Pharmaceuticals, Inc.